Biofrontera Inc Dossier
|
SectorHealth Care IndustryPharmaceuticals Beta (adjusted)0.85 Intrinsic Value $1.74median of 2 methodsbased on filings through 30 Jun 2026 Market Price $1.04Price as of 1 Oct 2026 Significantly undervaluedIntrinsic value is 67% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+67%) Data confidence Sign in to view data confidence Market Cap $15.4M Enterprise Value $15.4M Shares Outstanding 13.4M diluted Next Earnings Date11 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Biofrontera Inc. is transitioning into a high-margin commercial-stage dermatology player following its strategic asset acquisition in late 2025. By replacing its legacy 25% transfer-pricing model with a lower 12-15% earnout structure, the company has successfully expanded its gross margins to 80% and reduced its quarterly cash burn to near-zero. With a critical FDA PDUFA catalyst for superficial Basal Cell Carcinoma (sBCC) in September 2026 and positive clinical readouts in acne and expanded actinic keratosis, the company is well-positioned for double-digit revenue growth and near-term profitability, despite short-term going concern risks and regulatory friction regarding its RhodoLED XL lamp. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.75 Mean target$5.88 High · most bullish analyst$9.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $2.7515% The FDA issues a Complete Response Letter (CRL) or delays approval for the sBCC indication, and the ITC exclusion order severely restricts the import and sale of RhodoLED XL lamp components. Cash burn increases due to legal and remediation costs, forcing a highly dilutive equity raise to sustain operations as cash reserves dwindle. Base CaseCentral scenario $5.8860% Matches the consensus meanBiofrontera successfully navigates its going concern risk through organic sales growth of Ameluz and minor working capital adjustments. The sBCC indication is approved in late 2026, and the company files its sNDA for expanded AK use. Revenues grow to approximately $46.8 million in FY2026 and $54.7 million in FY2027, with the company achieving cash flow breakeven and modest profitability by 2027. Bull CaseUpside scenario $9.0025% The FDA approves the sBCC indication on or before the September 28, 2026 PDUFA date, making Ameluz the only PDT photosensitizer approved for sBCC in the US. Rapid commercial adoption, combined with successful resolution of the ITC lamp dispute and an expanded AK label, drives FY2027 revenues past $60 million, achieving sustained profitability ahead of schedule. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |